

Misetionamide (GP-2250) Publication Summary

(ver. April 2024)

2016

1. Majchrzak-Stiller B, Buchholz M, Vangala D, Hahn S, Pfirrmann R, Chromik Am, Braumann C, Uhl W. ID 0140: Taurolidine, substance 2250 and not gemcitabine display antineoplastic activity on **pancreatic stem-cell** like multicellular spheroid cultures. *Oncol Res Treat.* 2016;39 (Suppl 1), Abstract 140. <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\OncolResTreat - February 2016 - Majchrzak-Stiller B, et al. - pancreatic stem-cell.pdf>

2017

2. Buchholz M, Majchrzak-Stiller B, Hahn S, Vangala D, Pfirrmann R, Uhl W, Braumann C, Chromik AM. Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant **pancreatic carcinoma - in vitro and in vivo**. *BMC Cancer.* 2017;17(1). <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\BMC Cancer - 2017 - Buchholz, et al - Pancreatic carcinoma-in vitro and in vivo.pdf>

2019

3. Buchholz M, Majchrzak-Stiller B, Hahn S, Uhl W, Braumann C. Neue Therapieoption beim **Neuroendokrinen Tumor des Pankreas** – pNET. *Zeitschrift für Gastroenterologie.* 2019; 57(9). <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\Zeitschrift für Gastroenterologie - 2019 - Buchholz M, et al. Neuroendokrinen Tumor des Pankreas - pNET.pdf>

2020

4. Braumann C, Buchholz M, Majchrzak-Stiller B, Hahn S, Uhl W, Kasi A, Mueller T. **Metabolism-based GP-2250 in combination with gemcitabine** as a novel approach to pancreatic cancer: A mouse xenograft study. *Journal of Clinical Oncology* 2020 38:15_suppl, e16750-e16750 <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\J Clin Oncol. - 2020 - Braumann C., et al. Abstract - Metabolism-based GP-2250 in combination with gemcitabine.pdf>

2022

5. Baron C, Buchholz M, Majchrzak-Stiller B, Peters I, Fein D, Müller T, Uhl W, Hühn P, Strotmann J, Braumann C. Substance GP-2250 as a new therapeutic agent for

Misetionamide (GP-2250) Publication Summary

(ver. April 2024)

malignant peritoneal mesothelioma - a 3-D in vitro study. Int J Mol Sci. 2022;23(13):7923. <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\Intl Journal Molecular Sciences - June 2022 - Baron C, et al. - Malignant Peritoneal Mesothelioma.pdf>

6. Kasi A, Iglesias, JL. **A Phase 1/2 Trial of GP-2250** in Combination with Gemcitabine in Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed on Prior Treatment with FOLFIRINOX Chemotherapy. Poster TPS620 presented at the 2022 ASCO GI Cancers Symposium. S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\ASCO-GI - 2022 - Kasi_TPS620 - GP-2250TiP_Poster.pdf
7. Buchholz M, Strotmann J, Majchrzak-Stiller B, Hahn S, Peters I, Horn J, Müller T, Höhn P, Uhl W, Braumann C. New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the **Development of Secondary Resistances** In Vitro and In Vivo. Cancers 2022;14:2865. <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\Cancers - 2022-14-02685, Buchholz M, Strotmann J, et al - Development of Secondary Resistances.pdf>

2023

8. Majchrzak-Stiller B, Buchholz M, Peters I, Waschestjuk D, Strotmann J, Höhn P, Hahn S, Braumann C, Uhl W, Müller T, Möhler H. GP-2250, a novel anticancer agent, **inhibits the energy metabolism**, activates AMP-Kinase and impairs the NF-κB pathway in pancreatic cancer cells. J Cell Mol Med. 2023 Jul;27(14):2082-2092. doi: 10.1111/jcmm.17825. Epub 2023 Jun 30. <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\J Cellular Molecular Medi - 2023 - Majchrzak-Stiller - GP-2250 inhibits the energy metabolism .pdf>
9. Majchrzak-Stiller B, Buchholz M, Peters I, Strotmann J, Möhrke J, Zelichowski L, Oehlke L, Quensel C, Fein D, Höhn P, Müller T, Uhl W, Braumann C. **Oxathiazinane derivatives** display both antineoplastic and antibacterial activity: a structure activity study. J Cancer Res Clin Oncol. 2023 Sep;149(11):9071-9083. doi: 10.1007/s00432-023-04799-8. Epub 2023 May 12. <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\J Cancer Res Clin Oncol - 2023 - Majchrak-Stiller B, et al. - Oxathiazinane derivatives.pdf>
10. Barras M, Schmitz L, Braumann C, Uhl W, Skyrgan M, Buchholz M, Meyer T, Stockfleth E, Müller T, Becker JC, Gambichler T. An in vitro pilot study investigating

Misetionamide (GP-2250) Publication Summary

(ver. April 2024)

the antineoplastic effects of GP-2250 on **cutaneous squamous cell carcinoma** cell lines: preliminary results. *Dermato.* 2023; 3:85-86. <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\Dermato - 2023 - Barras M, et al. - Cutaneous squamous cell carcinoma.pdf>

11. Gambichler T, Majchrak-Stiller B, Peters I, Becker JC, Müller T, Uhl W, Abu Rached N, Buchholz M, Braumann C. The effect of GP-2250 on virus-negative **Merkel cell carcinoma** cell lines: preliminary results. *J Cancer Res Clin Oncol.* 2023 Jun 14. doi: 10.1007/s00432-023-04960-3. <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\Intl Journal Molecular Sciences - 2023 - Gambichler, et al. - Merkel cell carcinoma - DRAFT.pdf>
12. Kim MS, MS, Glassman D, Ahumada AL, et al. Mechanisms and rational combinations with GP-2250, novel oxathiazine derivative in ovarian **cancer**. *Cancer Research.* 2023; 87(7_supplement): 528. <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\Cancer Medicine - 2024 - Kim MS, et al. -an D, Ahumada Al, et al. Mechanisms and rational combinations with GP-2250, ovarian cancer.pdf>
13. Thilo Gambichler, Friederike Harnischfeger, Marina Skrygan, Britta Majchrzak-Stiller, Marie Buchholz, Thomas Müller, and Chris Braumann. In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated **Melanoma Cell Lines** and Benign Melanocytes. *Int. J. Med. Sci.* 2023, 24, 15336. <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\Intl. Journal Molecular Sciences 24-2023 - Gambichler T. et al. - Melanoma cell lines.pdf>
14. Britta Majchrzak-Stiller, Marie Buchholz, Ilka Peters, Daniel Waschestjuk, Johanna Strotmann, Philipp Höhn, Stephan Hahn, Chris Braumann, Waldemar Uhl, Thomas Müller, Hanns Möhler. GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates **AMP-Kinase and impairs the NF-kB pathway** in pancreatic cancer cells. *J Cell Mol Med.* 2023 Jul;27(14):2082-2092. doi: 10.1111/jcmm.17825. Epub 2023 Jun 30. <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\J Cellular Molecular Medi - 2023 - Majchrzak-Stiller, et al. AMP-Kinase and impairs the NF-kB pathway.pdf>
15. Mark S. Kim¹, Deanna Glassman¹, Adrian Lankenau Ahumada¹, Emine Bayraktar¹, Nicolas B. Jennings¹, Robiya Joseph¹, Sanghoon Lee¹, Robert L. Coleman², Anil K. Sood¹. Mechanisms and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. AACR 2023 Poster. <S:\Shared Folders\PANAVANCE>



1055 Westlakes Drive, Ste. 300, Berwyn, PA 19312
P +1.610.922.1910 | www.panavance.com

Misetionamide (GP-2250) Publication Summary

(ver. April 2024)

[DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\AACR - 2023 - GP-2250 in Ovarian Cancer Poster - Kim, Coleman, Sood, et al.pdf](#)

Misetionamide (GP-2250) Publication Summary

(ver. April 2024)

2024

16. R Duane Sofia, PhD, Kathryn M Martin, PharmD, James C Costin, MD. Antineoplastic Activity of GP-2250 in Vitro and in Mouse Xenograft Models. Anti-Cancer Drugs 2024, 35:183–1899. <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\Anti-Cancer Drugs - 2024 - Sofia RD, et al - GP-2250 in Vitro and in Mouse Xenograft.pdf>
17. Mark Kim, Deanna Glassman, Katelyn F Handley, Adrian Lankenau ahumada, Emine Bayraktar, Nicholas B. Jennings, Robiya Joseph, Robert L. Coleman and Anil K. Sood. Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. ACCEPTED. Cancer Medicine. 2024 <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\Cancer Medicine - 2024 - Kim MS, et al. -an D, Ahumada Al, et al. Mechanisms and rational combinations with GP-2250, ovarian cancer.pdf>
18. I.Peters; B. Majchrzak-Stiller ; M. Buchholz ; P. Höhn ; W. Uhl ; C. Braumann ; J. Strotmann Increasing the cytotoxic effectivity of 5FU, Irinotecan and Oxaliplatin on pancreatic cancer cells through combination with the novel anticancer agent GP-2250 in vitro (conference paper: Oncol Res Treat 2024;47(suppl 1):7–283, abstract 776) <S:\Shared Folders\PANAVANCE DUE DILIGENCE\Panavance Due Diligence 1\PUBLICATIONS\Oncol Res Treat - 2024 - Peters I, et al. - Cytotoxic effectivity of 5FU, Irinotecan and Oxaliplatin.pdf>